Compare TNON & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | ALZN |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.5M |
| IPO Year | 2021 | 2021 |
| Metric | TNON | ALZN |
|---|---|---|
| Price | $0.91 | $0.88 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 39.2K |
| Earning Date | 11-12-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | 76.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | N/A |
| Revenue This Year | $44.38 | N/A |
| Revenue Next Year | $39.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.96 | $0.84 |
| 52 Week High | $40.95 | $2.54 |
| Indicator | TNON | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 22.15 | 24.65 |
| Support Level | N/A | $0.84 |
| Resistance Level | $4.18 | $1.29 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 4.65 | 1.25 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.